Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep 1;49(1):107-10.
doi: 10.1097/QAI.0b013e3181820141.

Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana

Gregory P Bisson  1 , Adam Rowh, Rachel Weinstein, Tendani Gaolathe, Ian Frank, Robert Gross
Affiliations

Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana

Gregory P Bisson et al. J Acquir Immune Defic Syndr. .

Abstract

Background: Although adherence to antiretroviral therapy may be higher in sub-Saharan Africa, knowledge regarding the magnitude of adherence needed to maintain virological suppression in this setting is limited.

Methods: A case-control study among HIV-infected individuals initiating highly active antiretroviral therapy (HAART) in Gaborone, Botswana, was performed. Cases were randomly selected from subjects on HAART > or =6 months with plasma HIV-1 RNA levels (viral loads) >1000 copies/mL. Controls were randomly selected from subjects on HAART > or =6 months with all viral loads <400 copies/mL. HAART adherence was determined using pharmacy refill records.

Results: In total, 302 individuals were included; 57 cases were compared with 245 controls with respect to adherence levels on nonnucleoside reverse transcriptase inhibitor-based HAART. Median adherence levels, as measured using pharmacy refill patterns, were consistently high but differed among cases and controls (91%, interquartile range 83%-97% for cases vs 97%, interquartile range 91%-100% for controls, P < 0.001, rank-sum test). Adherence <95% was independently associated with virological failure (odds ratio 4.19, 95% confidence interval 2.2 to 8.3).

Conclusions: Very high rates of adherence were present in this setting, yet virological failure occurred nonetheless. Future work should explore other factors that might explain treatment failure in the setting of high levels of adherence.

PubMed Disclaimer

References

    1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30. - PubMed
    1. Gross R, Bilker WB, Friedman HM, et al. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109–2117. - PubMed
    1. Nachega JB, Hislop M, Dowdy D, et al. Adherence to non-nucleoside reverse transcriptase-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–573. - PubMed
    1. Wood E, Hogg RS, Yip B, et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:261–268. - PubMed
    1. Wood E, Hogg RS, Yip B, et al. “Discordant” increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30:159–166. - PubMed

Publication types